Dr. Clay Siegall, CEO who Prioritizes Cancer Patients

Home | Cancer | Dr. Clay Siegall, CEO who Prioritizes Cancer Patients

Clay Siegall endeavors to enhance the lives of cancer patients through biomedicine. He uses research and innovation to develop solutions for the patients and reduce their suffering. Siegall has 15 patents and has published several research findings and over 70 related articles.

Dr. Siegall supports legislations that help make the process of developing patient therapists efficient. Current therapies are not as effective as there are possibilities of relapse. He is encouraged by the nation’s efforts in prioritizing funding for biomedical research and approves of the current FDA model.

Dr. Clay Siegall is the Chairman, President, co-founder, and CEO, of Seattle Genetics. His leadership oversaw the creation of antibody cancer therapies such as ADCETRIS. He has also been on the fore front raising capital for the company and has since raised over 1.2 billion dollars through public-private partnerships and IPOs. Before Seattle Genetics, he worked with the National Cancer Institute, the National Institutes of Health, and Bristol-Myers Squibb Pharmaceutical Research Institute.

Seattle Genetics came into the market in 1998, when distinguishing chemotherapy meant for cancer cells and that for normal cells was a daunting task. The objective of the of the company was to improve the lives of people battling cancer through initiating better therapies that cater for current unmet needs. In depth research and pharmaceutical development, innovation, and passion helped transform Seattle into a top company in the antibody-drug conjugates sector. ADCTERIS is now globally used. The company has also acquired strategic licenses for the ADC technology with global medical manufacturing and distribution companies such as GlaxoSmithKline and has generated over 350 million dollars. 20 or more ADCs are now using their technology for clinical development.

Currently, Seattle Genetics is working on changing the existing treatment plan for Hodgkin Lymphoma by using ADCs with existing chemotherapies. They have been improving Adcetris to replace Bleomycin to treat the disease. According to the Investments Business daily, the Echelon-1 is set to increase Seattle Genetic’s value.

Clay sits on the Alder Bio Pharmaceuticals Board of Directors. He holds a Generics P.H.D and B.S in Zoology from George Washington University and the University of Maryland. The University of Maryland recognized Dr. Siegall as the alumnus of the year 2013 in Computer, Natural Science, and Math. Ernst &Young recognized him as the Pacific Northwest entrepreneur of 2012.

Leave a Reply

Your email address will not be published. Required fields are marked *